Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.

folfirinox
adenocarcinoma
breast ductal carcinoma
pdac
pancreatic ductal adenocarcinoma
  • 10 views
  • 28 Jun, 2022
  • 4 locations
Study of a New Technique for Imaging Pancreatic Cancer

The purpose of this study is to see how well the experimental imaging agent 89Zr-DFO-HuMab-5B1 attaches to pancreatic tumors, and to find out whether PET/CT scans done with this imaging agent produce better images of cancer.

adenocarcinoma
pancreatic neoplasm
pancreatic adenocarcinoma
EGFR
pancreatic ductal adenocarcinoma
  • 0 views
  • 12 May, 2022
  • 7 locations
Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer

This study is for the verification of biomarkers for pancreatic cancer treatment using small RNA liquid biopsy, combined with EUS-FNA tissues.

  • 0 views
  • 26 Jan, 2021
  • 1 location
PRECISE CURATE.AI Pilot Clinical Trial

In the current clinical context, drug dosing in oncology is dictated by toxicity. The optimal dosages of drugs in combinatory regimens for solid tumours are not clear, and the typical physician's decision on dose adjustment is a clinical judgement based on the degree of toxicity experienced by the patient. CURATE.AI …

neutrophil count
capecitabine
  • 0 views
  • 22 Mar, 2022
  • 2 locations
Gemcitabine Nab-paclitaxel Durvalumab and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

This phase II trial studies the effects of gemcitabine, nab-paclitaxel, durvalumab, and oleclumab in treating patients with primary pancreatic cancer that may be able to be removed by surgery (resectable/borderline resectable). Chemotherapy drugs, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either …

  • 0 views
  • 20 Nov, 2021
  • 1 location
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.

thromboplastin
liver metastasis
metastasis
platelet count
karnofsky performance status
  • 20 views
  • 30 Jun, 2022
  • 3 locations
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

This is a multi-center randomized double-blind placebo controlled trial of patients with high-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. The primary objective is to evaluate the effect of sulindac on the presence or absence of progression of IPMN after 3 years of treatment. Patients without contraindications will be …

  • 0 views
  • 14 Mar, 2022
  • 3 locations
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment

This trial is to evaluate the palliative effects of colchicine on primary hepatic malignancy using the Department of Health R.O.C. approved doses and methods of administration. Colchicine will be started from 2 tablets after meal twice per day (total 2 mg), adjust the dose ranging from total minimum 1.5 mg …

metastasis
colchicine
chemoembolization
cholangiocarcinoma
ct scan
  • 0 views
  • 26 Feb, 2022
  • 1 location
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

This phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is effective in treating patients with pancreatic cancer that can be surgically removed (resectable or borderline resectable), or that has spread to nearby tissue or lymph …

  • 0 views
  • 22 Mar, 2022
  • 1 location
Pancreatic Cancer Biomarker Study

This is a non-treatment, blood collection study to evaluate biomarker panels for the diagnosis and prognosis of pancreatic cancer.

  • 0 views
  • 27 Apr, 2022
  • 1 location